ORCA's Senior Management has been addressing and integrating reimbursement issues into the data collection processes since the mid-1990s. In the 1980s and 90s, each of our experts had been involved in a situation where a company's rewards for the hard work and expense of a successful FDA approval were unexpectedly delayed by the inability to obtain reimbursement. We knew there had to be a better way, and given the success of our team members, we think we have found it. Experience has shown that efforts to meet the requirements of the reimbursement reviewers are best started early in the project. ORCA will organize and facilitate your discussions with the appropriate agencies and suggest methods to acquire the necessary information early in the project. In some cases, our clients have not had the opportunity to start reimbursement data collection when the clinical trial started and were faced with the prospect of significant delays and cost overruns. ORCA, in these cases, has been able to use our vast clinical trial experience to reduce the amount of the delay by accelerating the collection of the clinical data. ORCA will guide you, upon FDA approval of your product, through the reimbursement processes with both governmental and third-party insurers using the years of accumulated experience of our specialists.